October 15, 2001
Nutrition 21 Providing Selenomax for NIH Study
PURCHASE, N.Y.--Nutrition 21's Selenomax® high-selenium yeast will be used in a study of selenium intervention in HIV-infected patients. The 18-month study is funded by the National Institutes of Health (NIH) and will be conducted at the University of Miami's Behavioral Medicine Research Center. It will include 280 patients and researchers will attempt to confirm smaller studies that selenium improves cardiac output, vascular function and other conditions in HIV populations.Nutrition 21 (www.nutrition21.com) previously supplied Selenomax to anotherNIH-funded cancer prevention study that was published in December 1996 in the Journal of the American Medical Association (JAMA).
You May Also Like